ALK and neuroblastoma: Crizotinib treatment could extend disease-free survival for ALK-positive NSCLC, ALCL and neuroblastoma.51, 52, 53 However, TKI resistance developed mostly due to secondary mutations.4, 54 Interestingly, acquired mutations affected the same hotspots (e.g., F1174) as those described in primary neuroblastomas.19, 20 Herein, we showed the F1174L-expressing SH-SY5Y and transfected SKN-AS neuroblastoma cells were sensitive to P36.